SeaStar Medical Holding Corporation (ICU) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $8.88M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSeaStar Medical Holding Corporation (ICU) trades at $3.13 with MoonshotScore 20/100 (Grade F). SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients.
Price as of Sep 11, 2026 · Last analyzed: Aug 30, 2026SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
ICU stock analysis for 2026: Analysts have set a consensus price target of $8.00 for SeaStar Medical Holding Corporation, suggesting 155.6% upside from the current price of $3.13. The AI MoonshotScore is 20/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
ICU: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Strongest side: Growth Durability (7/10, Moderate). Weakest side: Valuation (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SeaStar Medical Holding Corporation Company Overview
Who Are ICU's Competitors?
ICU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | — |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | — |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for ICU?
Financial-distress signal — its Altman Z-Score of -28.94 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 94% of our measures
- ● Price is current
- ● Latest filing 30 days ago
- ● Covered by analysts
Why 20?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.48 Volatility vs the market (Financial Strength)
- +0.48 Revenue growth (Growth)
- +0.41 Enterprise value vs sales (Valuation)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.78 Free cash flow yield (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 18 |
| 2026-08-26 | 22 |
| 2026-08-29 | 18 |
| 2026-09-01 | 19 |
| 2026-09-04 | 20 |
| 2026-09-07 | 20 |
| 2026-09-10 | 20 |
What changed?
The grade moved from 18 to 20 (+2).
What moved it up or down:
- +6 Valuation
- +6 Momentum
- +2 Financial Strength
Over the same 18 days the stock moved -7.5%.
How SeaStar Medical Holding Corporation Is Valued
SeaStar Medical Holding Corporation carries a market capitalization of $8.88M, placing it in the micro-cap category. Analyst price targets span from $8.00 to $8.00, with a consensus of $8.00. At the current price of $3.13, that implies approximately 156% upside potential.
SeaStar Medical Holding Corporation Financial Trajectory
SeaStar Medical Holding Corporation (ICU) reported $615K in revenue for Q2 FY2026, reflecting 24.2% growth compared to the prior quarter. The company recorded a net loss of $3.7M, with diluted EPS of $-0.91. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap its sector company. Across the four most recent quarters, ICU averaged $-0.98 in diluted EPS.
Key Financial Metrics
A current ratio of 2.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
SeaStar Medical Holding Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.94 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
SeaStar Medical Holding Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 11.1% above estimates on average.
Insider Activity
Over the past six months, SeaStar Medical Holding Corporation insiders filed 7 SEC Form 4 transactions — 0 sales and 7 purchases. On net that is roughly 34K shares acquired (about $2K) — insiders putting money in tends to read as conviction.
ICU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $615,000 | -$4M | -$0.91 |
| Q1 FY2026 | $495,000 | -$4M | -$0.90 |
| Q4 FY2025 | $420,000 | -$3M | -$0.80 |
| Q3 FY2025 | $183,000 | -$3M | -$1.30 |
Q2 FY2026 · filed 12 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
ICU Latest News
-
ICU: Continued Revenue Growth for QUELIMMUNE®
Yahoo! Finance: ICU News · Aug 17, 2026
-
SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...
GuruFocus.com · Aug 13, 2026
-
SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...
Yahoo! Finance: ICU News · Aug 13, 2026
-
SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript
Yahoo! Finance: ICU News · Aug 13, 2026
ICU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ICU.
Price Targets
Median: $8.00 (+155.6% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
ICU MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ICU scores 20/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
ICU: Continued Revenue Growth for QUELIMMUNE®
SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...
SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...
SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation Stock: Key Questions Answered
What does the AI Score mean for ICU?
ICU holds an AI Score of 20/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ICU a good stock?
Stock Expert AI does not rate ICU buy, sell or hold. SeaStar Medical Holding Corporation carries a MoonshotScore of 20/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for ICU?
SeaStar Medical Holding Corporation (ICU) holds an AI score of 20/100 (low). Analysts target $8.00 (+156%). Not financial advice.
How frequently does ICU data refresh on this page?
ICU's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ICU's recent stock price performance?
SeaStar Medical Holding Corporation (ICU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ICU overvalued or undervalued right now?
SeaStar Medical Holding Corporation (ICU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $8.00 (+156%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ICU?
Yes, most major brokerages offer fractional shares of SeaStar Medical Holding Corporation (ICU) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ICU's earnings and financial reports?
SeaStar Medical Holding Corporation (ICU) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ICU earnings announcements.
What should investors new to ICU understand first?
SeaStar Medical Holding Corporation (ICU) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 20/100. With a market cap of $8.88M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.